Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-01-14Clinical Trial Update: Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up [Phase 4]
Phase 4 clinical trial update assessing neurocognitive effectiveness in treatment of first-episode non-affective psychosis with a 3-year fol…
-
CLINICAL_TRIALS trial_result · 2020-01-09Clinical Trial Update: Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia [Phase 4]
Phase 4 trial update evaluating selective estrogen receptor modulators for women of child-bearing age with schizophrenia or schizoaffective …
-
FDA approval · 2020-01-08FDA Approved: HALOPERIDOL — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith Laboratories' haloperidol as an original generic (ANDA) product. The approval covers its use as a generic antipsyc…
-
CLINICAL_TRIALS trial_result · 2020-01-06Clinical Trial Update: An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia [Phase 3]
Open-label, long-term Phase 3 trial assessing aripiprazole intramuscular depot in schizophrenia; completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2019-12-30Clinical Trial Update: A Long-term Trial of OPC-34712 in Patients With Schizophrenia [Phase 3]
A long-term Phase 3 clinical trial of OPC-34712 in schizophrenia has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-12-26FDA Approved: ZIPRASIDONE MESYLATE — Original Application (Fosun Pharma USA Inc.)
FDA approved the original application for ziprasidone mesylate (generic) to treat schizophrenia and bipolar I disorder.
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: Clozapine for Cannabis Use in Schizophrenia [Phase 4]
Phase 4 trial updates the use of clozapine for cannabis use in individuals with schizophrenia; results posted in 2019.
-
FDA approval · 2019-12-26FDA Approved: ARIPIPRAZOLE — Original Application (VistaPharm, LLC)
FDA approved VistaPharm, LLC's original ANDA (212870) for a generic aripiprazole. This approval makes a generic version of aripiprazole avai…
-
FDA approval · 2019-12-23FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Mylan Institutional LLC)
FDA records a supplemental application approval for HALOPERIDOL DECANOATE from Mylan Institutional LLC under ANDA075440.
-
FDA approval · 2019-12-22FDA Approved: RISPERIDONE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
FDA approved a supplemental application for risperidone by Jubilant Cadista Pharmaceuticals Inc. This approval pertains to changes to the ap…
-
FDA approval · 2019-12-20FDA Approved: CAPLYTA — Original Application (Intra-Cellular Therapies, Inc)
The FDA approved CAPLYTA (lumateperone) in its original application by Intra-Cellular Therapies for the treatment of schizophrenia.
-
FDA approval · 2019-12-20FDA Approved: QUETIAPINE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for quetiapine from Macleods Pharmaceuticals Limited. The action provides regulatory approval for th…
-
FDA approval · 2019-12-20FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for quetiapine fumarate from Aurobindo Pharma Limited, allowing continued marketing of this generic …
-
CLINICAL_TRIALS trial_result · 2019-12-19Clinical Trial Update: Pediatric Open-Label Extension Study [Phase 3]
Phase 3 pediatric open-label extension study completed; results posted in 2019 for schizophrenia and autism conditions.
-
CLINICAL_TRIALS research · 2019-12-18Clinical Trial Update: Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating vitamin B6 and B12 for movement disorders induced by antipsychotics in schizophrenia.
-
FDA approval · 2019-12-11FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s supplemental application for quetiapine fumarate, a generic formulation under ANDA 090749.
-
FDA approval · 2019-12-11FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for Quetiapine Fumarate (ANDA 090120).
-
FDA approval · 2019-12-10FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for ARIPIPRAZOLE from Amneal Pharmaceuticals LLC (aripiprazole).
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness [NA]
Clinical trial update describing a concierge model of CAE plus long-acting injectable in individuals with schizophrenia at risk for treatmen…
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia [NA]
Open-label study investigating intranasal oxytocin for schizophrenia has terminated; results posted in 2019.
-
FDA label_change · 2019-12-04FDA Approved: LATUDA — Supplemental Application (Sumitomo Pharma America, Inc.)
FDA approved a supplemental application for LATUDA (lurasidone hydrochloride) from Sumitomo Pharma America, Inc.
-
FDA approval · 2019-11-29FDA Approved: ZIPRASIDONE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for ziprasidone submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2019-11-29FDA Approved: ZIPRASIDONE HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for ziprasidone hydrochloride from BluePoint Laboratories, authorizing its generic product to be mar…
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia [Phase 3]
Phase 3 trial of Lu AF35700 in treatment-resistant schizophrenia completed; results posted.
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: Theta Burst Stimulation for Schizophrenia [NA]
A completed clinical trial evaluating theta burst stimulation for schizophrenia and schizoaffective disorder; results posted in 2019.